Notícias

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively tra

By Julie Steenhuysen and Christy Santhosh CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a late-

By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes were on track to open higher on Wednesday after a tech-led selloff in the previous session as investors assessed fresh

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

A successful cancer vaccine would be an important new market for Moderna, whose investors have been impatient for it to expand beyond its Covid prevention vaccine.

The Phase 3 trial tested Intismeran Autogene with Merck’s blockbuster immunotherapy Keytruda.

Moderna skyrocketed and Merck jumped on strong late-stage trial results for their cancer vaccine in melanoma patients Wednesday.

Stock Market Today: The Dow Jones index rises Wednesday ahead of the Fed minutes. Nvidia supplier SK Hynix jumps on a stock buyback.

Investing.com - Investing.com -- U.S. stock futures edged lower in Asian trading on Wednesday, pointing to a cautious start on Wall Street after major indexes closed lower for a third consecutive session, as a global bond selloff and elevated oil prices kept investors wary and pressured rate-sensitive technology stocks.

Shares of US vaccine-maker Moderna soared 60 per cent in pre-market trading after the company reported successful results for a melanoma cancer...

Stock markets are waited on minutes of the Fed's most recent monetary policy meeting for any clues about the forward path on interest rates.

Wall Street futures pointed largely sideways pre-bell Wednesday, as a global bond sell-off eased, an

An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said. Shares in Moderna jumped about 10% premarket, while Merck also climbed around 6%.

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

A successful cancer vaccine would be an important new market for Moderna, whose investors have been impatient for it to expand beyond its Covid prevention vaccine.

↗️ SK Hynix (SKHY, KR:000660): The chip giant announced plans for a $28 billion buyback. Its U.S.-listed shares jumped in premarket trading. Earlier, its Korean shares closed nearly 10% lower amid a selloff in Asia.

Stocks continued to be under pressure after the S&P 500 fell for three days in a row.

Sandisk, Micron, Credo and many other chip and AI stocks dived a day after bullish moves. The major indexes are wiping out recent gains.

<p>Free cash flow funds are having a moment, but many of the traditional FCF strategies miss the bigger picture and greater return potential. Victory Capital’s Mannik Dhillon breaks down how <a href="https://www.etf.com/VFLO"><strong>VFLO</strong></a><strong> </strong>turned a forward-looking value investing strategy into one of the decade’s biggest ETF launches, all without a single Mag 7 stock, in this episode of <em>Behind the Ticker. </em></p>

It’s all about retail earnings this week with Walmart, Home Depot, Target and Alibaba all set to report.

Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for […]

mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.

On this episode of Stock Movers: - RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week. - Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround. - Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom.

Net loss improved 5% on international partnerships and manufacturing gains.

MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.

Moderna (NasdaqGS:MRNA) has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine targeting Bundibugyo ebolavirus. The program addresses a strain of Ebola that currently has no approved vaccine and is positioned as part of Moderna's broader infectious disease portfolio. The trial involves collaboration with CEPI and Canadian public health authorities, with a stated focus on access for low and middle income countries. This kind of targeted vaccine work highlights...

Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call